Please login to the form below

Not currently logged in
Email:
Password:

Mylan’s president Tony Mauro elected chair of GPhA

Will lead trade body for US generics industry during important time for market

Tony Mauro - GPhATony Mauro, president of Mylan Pharmaceuticals, has been elected as the new chair of the US-based Generic Pharmaceutical Association (GPhA).

Mauro, who previously served as the trade body's vice chair, replaces Watson Pharmaceutical's president and CEO Paul Bisaro and will serve in the position for one year.

Commenting on his appointment, Mauro said: “With growing populations, economic recessions and increasing healthcare costs, the need for widespread access to more affordable medicine has never been so great.

“The generic pharmaceutical industry, which accounts for 78 per cent of all prescriptions dispensed in the US, has played an important role in saving the US healthcare system and consumers an estimated $931bn over the past decade."

Mauro has been at Mylan for 15 years, holding several roles prior to president, including chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of strategic development,North America, and vice president of sales, North America.

In his new role at the GPhA, Mauro will work closely with the group's president and CEO Ralph Neas, who has been active in representing the US generics industry with regards to ongoing drug shortage issues in the country.

The US the Food and Drug Administration's (FDA) recent generics user-fee scheme will increase funding for the regulator and should help it plough through a backlog of more than 2,000 generic drug applications.

This is an increasingly important time too for the global generics market, which is set to grow by $100bn over the next five years thanks to a raft of patent expiries and strong demand in emerging markets.

29th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics